Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$86.88 USD

86.88
215,820

+2.51 (2.97%)

Updated Jul 8, 2024 04:00 PM ET

After-Market: $86.88 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.

Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises

Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.

Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.

United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales

United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates

Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates

Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.

Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates

Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales

Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 78.67% and 17.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates

Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.

Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised

Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.

Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised

Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.

BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.

Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.